^
Association details:
| Biomarker: | BRCA2 mutation + ER positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | fulvestrant (Selective estrogen receptor degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study)
Published date:
02/14/2023
Excerpt:
In this randomised, open-label, multi-centre, parallel-controlled phase 2 FRIEND study, 145 postmenopausal ER+/HER2- ABC patients were assigned into fulvestrant...the mutations of c-MYC and BRCA2 were significant factors for the fulvestrant superiority over exemestane and showed that c-MYC and BRCA2 mutations led to a longer PFS time in the fulvestrant treated group of patients compared to the exemestane group (p = 0.049, p = 0.039)....Fulvestrant significantly increased overall PFS for ER+/HER2- ABC patients and was well tolerated.
DOI:
10.1016/j.ejca.2023.02.007
Trial ID:
